About: HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
Creator	Wang, Tao Chen, Alan Hartman, Zachary Heiland, Teri Lei, Gangjun Liu, Cong-Xiao Lyerly, Herbert Wei, Junping Xu, Renhuan Yang, Xiao-Yi
source	PMC
abstract	BACKGROUND: The advent of immune checkpoint blockade antibodies has demonstrated that effective mobilization of T cell responses can cause tumor regression of metastatic cancers, although these responses are heterogeneous and restricted to certain histologic types of cancer. To enhance these responses, there has been renewed emphasis in developing effective cancer-specific vaccines to stimulate and direct T cell immunity to important oncologic targets, such as the oncogene human epidermal growth factor receptor 2 (HER2), expressed in ~20% of breast cancers (BCs). METHODS: In our study, we explored the use of alternative antigen trafficking through use of a lysosome-associated membrane protein 1 (LAMP) domain to enhance vaccine efficacy against HER2 and other model antigens in both in vitro and in vivo studies. RESULTS: We found that inclusion of this domain in plasmid vaccines effectively trafficked antigens to endolysosomal compartments, resulting in enhanced major histocompatibility complex (MHC) class I and II presentation. Additionally, this augmented the expansion/activation of antigen-specific CD4+ and CD8+ T cells and also led to elevated levels of antigen-specific polyfunctional CD8+ T cells. Significantly, vaccination with HER2-LAMP produced tumor regression in ~30% of vaccinated mice with established tumors in an endogenous model of metastatic HER2+ BC, compared with 0% of HER2-WT vaccinated mice. This therapeutic benefit is associated with enhanced tumor infiltration of activated CD4+ and CD8+ T cells. CONCLUSIONS: These data demonstrate the potential of using LAMP-based endolysosomal trafficking as a means to augment the generation of polyfunctional, antigen-specific T cells in order to improve antitumor therapeutic responses using cancer antigen vaccines.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1136/jitc-2019-000258
bibo:pmid	32532838
has license	cc-by-nc
sha1sum (hex)	0c984cfa8dce61e5c499ef1500f676a7c6a5e401
schema:url	https://doi.org/10.1136/jitc-2019-000258
resource representing a document's title	HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
has PubMed Central identifier	PMC7295440
has PubMed identifier	32532838
schema:publication	J Immunother Cancer
resource representing a document's body	covid:0c984cfa8dce61e5c499ef1500f676a7c6a5e401#body_text
is schema:about of	named entity 'tumor' named entity 'membrane protein' named entity 'tumor' named entity 'assay' named entity 'oncogene' named entity 'antitumor' named entity 'electroporation' named entity 'HER2' named entity 'CD8+ T cells' named entity 'epitopes' named entity 'electroporation' named entity 'CD4' named entity 'lysosomes' named entity 'vaccination' named entity 'HER2' named entity 'therapeutic agent' named entity 'qRT-PCR' named entity 'immunosuppression' named entity 'Invitrogen' named entity 'immune responses' named entity 'cell surface' named entity 'mice' named entity 'Abcam' named entity 'immune responses' named entity 'HER2' named entity 'HER2' named entity 'self-antigens' named entity 'TSA' named entity 'small molecule inhibitors' named entity 'vaccination' named entity 'HER2' named entity 'C-terminus' named entity 'chemokine' named entity 'HER2' named entity 'HER2' named entity 'Western blot' named entity 'PBS' named entity 'immunotherapies' named entity 'therapeutic benefit' named entity 'CD8+ T cell' named entity 'MHC' named entity 'immune responses' named entity 'HER2' named entity 'CD8+' named entity 'allergic' named entity 'HER2+' named entity 'multipotent' named entity 'immune responses' named entity 'HER2+' named entity 'mice' named entity 'HER2' named entity 'tumors' named entity 'lysosomes' named entity 'HER2' named entity 'CD4+' named entity 'CD4+ T' named entity 'intramuscular' named entity 'tumor' named entity 'Life Technologies' named entity 'Immunological tests' named entity 'CD8+' named entity 'ICHOR' named entity 'flow cytometry' named entity 'West Nile Virus' named entity 'HER2' named entity 'antitumor' named entity 'HER2' named entity 'vaccination' named entity 'adjuvants' named entity 'Granzyme B' named entity 'antitumor' named entity 'OVA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software